Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, talks on the benefits of next-generation sequencing (NGS) in Waldenström’s macroglobulinemia (WM). NGS has identified MYD88 signaling mutations, which is seen in 95% of patients, as well as CXCR4 mutations present in around 40% of patients, pathing the way for treatment options to target aberrant MYD88 and CXCR4 signaling in WM. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.